Check out this morning's top movers from around Wall Street, compiled by The Fly. 

HIGHER -

• Mesoblast (MESO) up 59% after announcing a single dose of rexlemestrocel-L resulted in substantial and durable reductions in heart attacks, strokes and cardiac death in the Phase 3 DREAM-HF trial
• Eli Lilly (LLY) up 14% after announcing Donanemab met the primary endpoint of change from baseline to 76 weeks in the Integrated Alzheimer's Disease Rating Scale, slowing decline by 32% relative to placebo, which was statistically significant
• Secoo Holding (SECO) up 20% after receiving a preliminary non-binding proposal letter from Richard Rixue Li, founder, chairman of the board and CEO of the company, proposing to acquire all of the outstanding class A ordinary shares of the company not owned by him or his affiliates for $3.27 per American depositary share, or $6.54 per Class A share in cash in a going private transaction
• 500.com (WBAI) up 12% after entering into a definitive purchase agreement with certain non-U.S. persons pursuant to which the company expects to issue approximately $14.4M worth of its Class A ordinary shares as consideration to acquire bitcoin mining machines
• Gilead (GILD) up 1% after raising its FY20 adjusted EPS and revenue outlook

LOWER -

• DexCom (DXCM) down 3% after reporting preliminary Q4 revenue and providing FY20 guidance
• Twitter (TWTR) down 8% after permanently suspending the @realDonaldTrump account
• Lululemon (LULU) down 3% after announcing that the company now expects revenue and earnings to be at the high end of its prior range of expectations for Q4
• NCR Corp. (NCR) down 1% after confirming that it has submitted an offer to acquire all outstanding shares of Cardtronics (CATM) for $39 per share in cash